Pfizer Stock Drops 4.83% in Four Days Amid Probe, Trading Volume Ranks 39th
1min read On March 27, 2025, pfizer (PFE) experienced a decline of 0.79%, marking its fourth consecutive day of losses, with a total decrease of 4.83% over the past four days. The trading volume for the day was 12.67 billion, placing it at the 39th position in the daily stock market rankings.
Pfizer's stock has been under pressure due to reports that U.S. prosecutors are investigating claims that the company intentionally delayed announcing the success of its COVID-19 vaccine for political reasons. This probe, reported by The Wall Street Journal, has raised concerns about the timing of Pfizer's vaccine results and its potential impact on public health decisions.
Ask Aime: Will Pfizer's stock continue to decline due to the ongoing investigation into its COVID-19 vaccine's timing and impact on public health decisions?
Despite the investigation, analysts at Citi have maintained a Neutral rating on Pfizer stock with a price target of $27.00. The firm believes that the probe is unlikely to have a significant long-term impact on the company's operations or financial performance. Citi's analyst, Geoff Meacham, noted that Pfizer's strong portfolio of drugs and vaccines, along with its robust pipeline, should continue to drive growth in the coming years.
Pfizer's fourth-quarter earnings report showed a 21.9% year-over-year increase in revenues, totaling $17.76 billion. This exceeded analysts' expectations by 3%, highlighting the company's strong performance in the quarter. However, the stock has declined by 3.8% since the earnings release, reflecting investor concerns about the ongoing probe and the broader challenges facing the pharmaceutical industry.
Looking ahead, Pfizer is well-positioned to benefit from advancements in precision medicine and the increasing adoption of AI in drug development. However, the company also faces headwinds such as regulatory scrutiny, pricing pressures, and patent cliffs for key blockbuster drugs. Despite these challenges, Pfizer's strong portfolio and innovative pipeline should help it navigate the complex operating environment and continue to deliver value to shareholders.
